WO2024018442 - PREFERENTIAL DEPLETION OF TCF1+ PROGENITOR T-CELLS IN SEVERE COVID-19 AS MEDIATED BY INTERLEUKIN 12 (IL-12)
National phase entry is expected:
Publication Number
WO/2024/018442
Publication Date
25.01.2024
International Application No.
PCT/IB2023/057478
International Filing Date
22.07.2023
Title **
[English]
PREFERENTIAL DEPLETION OF TCF1+ PROGENITOR T-CELLS IN SEVERE COVID-19 AS MEDIATED BY INTERLEUKIN 12 (IL-12)
[French]
DÉPLÉTION PRÉFÉRENTIELLE DE LYMPHOCYTES T PROGÉNITEURS TCF1+ DANS LA COVID-19 DE FORME GRAVE TELLE QUE MÉDIÉE PAR L'INTERLEUKINE 12 (IL-12)
Applicants **
RUDD, Christopher E.
Inventors
RUDD, Christopher E.
Priority Data
63/391,660
22.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3863 | |
| EPO | Filing, Examination, Granting | 26504 | |
| Japan | Filing, Examination, Granting | 3384 | |
| South Korea | Filing, Examination, Granting | 4637 | |
| USA | Filing, Examination, Granting | 13190 |
Total:
51,578
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS- Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.[French]
La maladie à coronavirus 2019 (COVID-19) pandémique provoquée par le coronavirus du syndrome respiratoire aigu sévère 2 (SARS-CoV-2) reste une menace pour la santé publique globale. Tandis que certains individus présentent de légers symptômes, d'autres développent une maladie de forme grave conduisant à une lymphopénie grave et à la mort. L'invention concerne des méthodes permettant de déterminer si un sujet souffrant d'une infection par le SARS-Cov-2 est plus susceptible de souffrir d'une maladie de forme grave ou légère. L'invention concerne également des méthodes permettant de prédire si un sujet souffrant d'une infection par le SARS-Cov-2 d'une maladie modérée va progresser vers une maladie de forme plus grave et des méthodes permettant de traiter des patients atteints d'une infection par le SARS-Cov-2 ainsi que les membres de leur famille.